Achondroplasia Treatment to Skeletal Dysplasia Market Growth: Study

Prominent pharmaceutical companies are emphasizing on major drug development campaigns, conducting extensive clinical trials and laboratory experiments, expected to contribute to future growth

Fact.MR, Rockville MD: The global skeletal dysplasia market is expected to yield substantial gains through 2021, as regulatory authorities around the world fast track approvals of potential drug candidates, according to an ongoing study being conducted by research firm Fact.MR. Long-term projections also appear optimistic, with a robust growth rate likely to prevail through 2031.

Growth is largely expected to be underpinned by extensive research for treating achondroplasia. Being the most frequent type of short-limbed dwarfism, achondroplasia affects at least 1 in 15,000 to 40,000 newborn infants worldwide. However, rates of incidences vary with different geographies. For instance, there is at least 1 case in every 6400 births across Denmark, and 1 in every 10000 births in Latin America.

Key pharmaceutical giants are capitalizing on furthering research on new drug candidates. A case in point is of Astellas Pharma Inc. which, in December 2020, partnered with the Noriyuki Tsumaki Laboratory to develop the ASP5878 candidate. Likewise, in 2019, Ascendis Pharma A/S announced the conferment of orphan drug status for its TransCon C-Type Natriuretic Peptide (CNP) to treat achondroplasia. Such developments are expected to bolster expansion prospects in the long-run.

“As the global pandemic crisis incidence recedes, the global healthcare fraternity is recalibrating its research and development priorities, providing major impetus to studies concerning future skeletal dysplasia drug candidates, opening up possible revenue ecosystems in the long-run,” comments the Fact.MR analyst.

Request a report sample to gain comprehensive insights at

Key Takeaways from Fact.MR’s Skeletal Dysplasia Market Study

  • By disease type, treatment for achondroplasia is likely to emerge as the most promising research area
  • Patients to exhibit significant tilt towards growth hormones based skeletal dysplasia treatment
  • US to receive credible impetus, driven by ongoing clinical trials for verifying efficacy of drug candidates such as vosoritide
  • High incidence of dwarfism to heighten skeletal dysplasia treatment research across the UK
  • Germany making significant strides, especially with regard to prenatal sonographic diagnosis for providing timely treatment
  • India and China to emerge as attractive growth hotspots, driven by increased healthcare infrastructure development

Skeletal Dysplasia Market- Prominent Drivers

  • Heightening government funding for drug development and research is driving skeletal dysplasia treatment growth
  • Manufacturers are deploying a combination of hormonal-cum-medicinal treatment, opening up numerous growth opportunities
  • Healthcare experts are touting spinal fusion and decompression procedures, promoting heightened research in skeletal dysplasia treatment

Skeletal Dysplasia Market- Key Restraints

  • Limited availability of potential drug candidates is hampering skeletal dysplasia market growth
  • Prolonged approval schedules from regulatory authorities are delaying new therapeutic approaches availability

Discover more about the skeletal dysplasia market with figures, data tables and the table of contents. You will also find detailed market segmentation on

Competitive Landscape

Key players operating in the skeletal dysplasia market include Dr. Reddy’s Laboratories, Celgene Corporation, Cipla Inc., Novartis AG, Teva Pharmaceutical Industries, Merck Group, F. Hoffmann-La Roche AG, Eli Lilly, Abbott Laboratories, Clementia Pharmaceuticals, Regeneron Pharmaceuticals Inc., and BioMarin Pharmaceuticals Inc. among others.

Manufacturers are concentrating on capacity expansion approaches by relying on strategic moves such as acquisitions, partnerships and collaborations. For instance, in April 2019, Ipsen acquired Clementia Pharmaceuticals, with the objective of expanding its polovarotene drug candidate portfolio, used to treat adult and pediatric rare bone disorders.

Recently, in November 2020, the US Food & Drug Administration accepted the New Drug Application (NDA) for vosoritide, an investigational once daily injection analog of the C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most prominent type of skeletal dysplasia responsible for inducing dwarfism amongst individuals. The approval status is likely to be conferred by August 2021.

More Insights on the Skeletal Dysplasia Market

In its latest report, Fact.MR offers unbiased analysis of the global skeletal dysplasia market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of disease type (thanatophoric dysplasia, campomelic dysplasia, achondroplasia, osteogenesis imperfecta, achondrogenesis and others), treatment type (growth hormones, parathyroid hormones, mast cell inhibitors and muscle relaxants) and distribution channel (hospital pharmacies, retail pharmacies, drug stores and online pharmacies) across five regions (North America, Latin America, Europe, Asia-Pacific and Middle East & Africa)

Request more information about Report Methodology

Explore Fact.MR’s Coverage on the Healthcare Domain

Ultralow Temperature Freezer Market: A recent study by Fact.MR on the ultra-low temperature freezer market offers a 10-year forecast. The study analyzes crucial trends that are currently determining the growth of the ultra-low temperature freezer market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players.

Indirect Calorimeter Market: Fact.MR’s indirect calorimeter market study offers a decade long forecast, explicating on vital dynamics such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of indirect calorimeters. The study also provides the dynamics that are responsible for influencing the future status of the indirect calorimeter market over the forecast period.

Medical Education Market: A detailed assessment of the medical education market value chain and business execution across the regional markets has been covered in the report. A list of prominent companies operating in the medical education market along with their product portfolio enhances the reliability of this comprehensive research study.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Source: Fact.MR

Back to news